Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation
Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...
StockStory.org on MSN2h
1 Stock Under $50 with Solid Fundamentals and 2 to Turn Down
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They ...
Guardant Health (GH) Receives a Buy from Barclays
In a report released today, Luke Sergott from Barclays maintained a Buy rating on Guardant Health (GH – Research Report), with a price target ...
Reuters20d
Guardant Health sues rival Natera over cancer-testing trade secrets
Feb 21 - Medical diagnostics company Guardant Health (GH.O), opens new tab has sued rival Natera (NTRA.O), opens new tab in California federal court for allegedly stealing trade secrets related to ...
Business Wire8d
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening …
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Dak Prescott’s ...
Forbes21d
Guardant Health
Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions ...
Seeking Alpha28d
Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
While there is significant competition, and the market winners are yet to be determined, Guardant Health is well positioned. Guardant has faced skepticism due to its large losses and the ...
Guardant Health (NASDAQ:GH) Price Target Raised to $52.00
Guardant Health (NASDAQ:GH – Free Report) had its target price lifted by Morgan Stanley from $42.00 to $52.00 in a report issued on Thursday,Benzinga reports. They currently have an overweight rating ...